UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter
  
Dividing line
An FDA advisory committee was divided on UroGen's application for bladder cancer, as well as future approval standards. (Shutterstock)

More from US Advisory Committees

More from Pink Sheet